Equities Analysts Offer Predictions for APLS FY2026 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Apellis Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will earn ($0.80) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $44.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. During the same quarter in the previous year, the firm earned ($0.54) earnings per share. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year.

A number of other research firms have also recently weighed in on APLS. Wells Fargo & Company raised their price target on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an “equal weight” rating in a report on Monday, June 2nd. Bank of America downgraded shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $41.00 to $23.00 in a research note on Friday, May 9th. Citigroup cut their price objective on Apellis Pharmaceuticals from $49.00 to $41.00 and set a “buy” rating on the stock in a report on Thursday, May 22nd. Needham & Company LLC dropped their price target on Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Finally, Mizuho reduced their target price on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, May 14th. Nine analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.05.

Apellis Pharmaceuticals Trading Up 0.7%

Shares of Apellis Pharmaceuticals stock opened at $19.41 on Tuesday. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $43.76. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a market cap of $2.44 billion, a price-to-earnings ratio of -9.62 and a beta of 0.68. The company’s fifty day simple moving average is $18.40 and its 200-day simple moving average is $25.53.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas boosted its holdings in Apellis Pharmaceuticals by 9.4% during the 4th quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company’s stock valued at $691,000 after acquiring an additional 1,864 shares during the period. Entropy Technologies LP bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth approximately $445,000. Ameriprise Financial Inc. increased its stake in shares of Apellis Pharmaceuticals by 2.6% in the fourth quarter. Ameriprise Financial Inc. now owns 882,801 shares of the company’s stock worth $28,170,000 after buying an additional 22,507 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Apellis Pharmaceuticals by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 212,887 shares of the company’s stock valued at $6,793,000 after buying an additional 21,822 shares during the period. Finally, Nuveen Asset Management LLC increased its position in shares of Apellis Pharmaceuticals by 44.1% in the fourth quarter. Nuveen Asset Management LLC now owns 491,107 shares of the company’s stock valued at $15,671,000 after acquiring an additional 150,384 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).